PTPN9 IS A NEGATIVE REGULATOR OF HER3 PHOSPHORYLATION AND A PROGNOSTIC BIOMARKER IN HER2 POSITIVE BREAST CANCER

PTPN9 IS A NEGATIVE REGULATOR OF HER3 PHOSPHORYLATION AND A PROGNOSTIC BIOMARKER IN HER2 POSITIVE BREAST CANCER

Bibliographic Details
Main Authors:	Gijsen, M, Tang, P, Leung, W, Roxanis, I, Kong, A
Format:	Conference item
Published:	2012

Similar Items

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer
by: Gijsen, M, et al.
Published: (2010)

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
by: Merel Gijsen, et al.
Published: (2010-12-01)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: Anna Burguin, et al.
Published: (2020-01-01)

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
by: Caroline Rönnlund, et al.
Published: (2024-02-01)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
by: Shohei Shikata, et al.
Published: (2023-11-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
by: Laura Pizzuti, et al.
Published: (2021-07-01)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
by: Maria Vittoria Dieci, et al.
Published: (2019-11-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
by: Alaa Mohamed Maria, et al.
Published: (2018-06-01)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)

Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer
by: Tao Rui, et al.
Published: (2022-05-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
by: Emma Zattarin, et al.
Published: (2023-04-01)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
by: Goodman Julie E, et al.
Published: (2010-11-01)

THE ROLE OF ADAM17 IN HER2 MODERATELY EXPRESSING BREAST CANCER
by: Feldinger, K, et al.
Published: (2012)

Prognostic Impact of Low Estrogen and Progesterone Positivity in Luminal B (HER2 Negative) Breast Cancer
by: Jasmina Rajc, et al.
Published: (2018-01-01)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
by: Gijsen, M, et al.
Published: (2010)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
by: Konstantinos Venetis, et al.
Published: (2022-03-01)

Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type
by: Anne-Sophie Wegscheider, et al.
Published: (2021-07-01)

Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
by: Ishita Gupta, et al.
Published: (2020-09-01)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
by: Sibylle Loibl, et al.
Published: (2022-09-01)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
by: William Jacot, et al.
Published: (2021-12-01)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
by: Binliang Liu, et al.
Published: (2022-07-01)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
by: Yoshiya Horimoto, et al.
Published: (2022-03-01)

AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer
by: Khalid N. Al-Zahrani, et al.
Published: (2021-05-01)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
by: Atif Ali Hashmi, et al.
Published: (2018-08-01)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)

STARD3: A New Biomarker in HER2-Positive Breast Cancer
by: Massimo Lodi, et al.
Published: (2023-01-01)

MAF1 is a predictive biomarker in HER2 positive breast cancer.
by: Stephanie Cabarcas-Petroski, et al.
Published: (2023-01-01)

Role of p53 and Her2/Neu as a prognostic biomarker in breast carcinoma
by: Anamika Gupta, et al.
Published: (2023-01-01)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
by: Atul Batra, et al.
Published: (2021-02-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
by: Bradley M. Turner, et al.
Published: (2021-11-01)

Immunotherapy for HER-2 positive breast cancer
by: Tingting Yang, et al.
Published: (2023-03-01)

Bevacizumab in the treatment of HER2-negative breast cancer
by: Vito Lorusso
Published: (2008-11-01)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
by: Nindo B. Punturi, et al.
Published: (2021-05-01)